Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome

Hospices Civils de Lyon154 enrolled

Overview

Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure. Sodium overload is one of the main causes leading to the occurrence or the exacerbation of this syndrome. Some patients have a massive sodium retention on which medications are not effective enough. These patients have no further therapeutic options because of the refractory congestion and a 3-months mortality rate around 15%, frequent rehospitalization (3-months rehospitalization rate at 71%) and an excessively impaired quality of life. For those refractory heart failure with cardio renal syndrome, nephrology departments resort to non-medication sodium extraction (hemodialysis, peritoneal dialysis, isolated ultrafiltration). Between 2002 and 2008, 927 French patients would have start dialysis in this situation. In 2013, 174 patients start dialysis in 97 dialysis centers. French National Authority of Health recently published new Good Practice Guidance thereupon, strengthened by the increasing number of publications and the widespread use of this technique. There is therefore a consensus among professionals about the benefits of such a technique in those indications. However, bibliographical data are not strong enough to support a strong level of evidence. None of foresight strategies have been compared to others in a proper randomized controlled trial, and there is no clue about any suspected superiority from one strategy to another. So far, the investigators propound invasive, expensive and not validated techniques to patients with functional and vital prognosis altered. The investigators think it's essential to prove the efficacy of such an approach. They wish to quantify those techniques impact on rehospitalization, with a consideration for the potential survival impact. It seems unethical to evaluate separated techniques, taking in account that patients with severe heart failure will switch from one technique to another among their care. It is therefore crucial to validate benefits from an invasive procedure (hemodialysis, peritoneal dialysis, isolated ultrafiltration) compared to a medication-restricted care.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Interventions

ULTRAFILTRATIONPROCEDURE

Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner. Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance. Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device.

ENHANCED MEDICAL TREATMENTPROCEDURE

* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample * Medical care adjustment in order to apply European and American guidance for chronic heart failure care * Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed * Physical rehabilitation suggestions by a physiologist * Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Severe heart failure with recurring congestive symptoms and at least one the following criteria : * At least 2 hospitalization \> 24 hours for congestive symptoms among the 12 months before the inclusion, whose latest one was in the 6 months before the inclusion * Persistent congestive symptoms throughout 30 days (case history) before the randomization: dyspnea NYHA III or IV, lower limbs edema and/or ascites. * Diuretic treatment with at least 250mg furosemide per day (or 6mg bumetanide)during at least 1 month * Cardiac medical treatment enhanced by the European cardiology society guidance (except intolerance, and/or contraindication) and according to patient cardiologist. * Non terminal kidney disease or failure : estimated glomerular filtration rate (GFR) (CKD-Epi formula) between 20 and 90 mL/min/1.73m² (or GFR estimated between 60 and 90 mL/min/1.73m² with proteinuria and/or hematuria) and urea rate under 50mmol/L Exclusion Criteria: * Cardiogenic shock or situations that contraindicate the ultrafiltration technique elsewhere than shock room * Patient who already had long course ultrafiltration for more than 3 months, or not available because of end-stage renal failure * Biventricular pacemaker implementation, single or dual chamber pacemaker implementation, or defibrillator implementation up to 15 days before the inclusion * Vasoactive drugs ambulatory treatment (dobutamine, dopamine, adrenalin, noradrenalin) * General condition incompatible with any ultrafiltration techniques * Age under 18 * Pregnant or lactating women * Law-protected patients * Patients that can't submit to the follow-up for geographical, social or mental reasons * Unwillingness to be treated by ultrafiltration techniques * Patients who don't belong to the national social security system, or similar system.

Outcomes

Primary Outcomes

death and/or unscheduled hospitalization

The primary outcome measure is a combined measure including death whatever the cause, and/or unscheduled hospitalization for acute decompensated heart failure. For each groups, deaths, cause and time of deaths will be recorded. Hospitalization date, duration, location, and reason will be recorded. The "hospitalization" setting and the "acute decompensated heart failure" setting will be endorsed by an event validation committee.

Time frame: up to 12 months post-randomization

Secondary Outcomes

Survival

number of days spent alive and not hospitalized

Time frame: 12 months

Survival

Intervention effect on one-year overall survival

Time frame: 12 months

Hospitalization for acute decompensated heart failure

Intervention effect on : * Period before first unscheduled hospitalization for acute decompensated heart failure * Number and duration of hospitalizations for acute heart failure (scheduled or not) throughout the year * Number and duration of unscheduled hospitalization for acute heart failure throughout the year.

Time frame: up to 12 months post- randomization

Change in NYHA classification

New York Health Association - Measurement scale to classify heart failure in 4 stages (stage 1 ; no symptoms)

Time frame: randomization day and 12 months post randomization.

Change in 6MWT - Six-Minute Walk Test

Six-minute walk test with an experimented physiologist. The distance in meters is retained.

Time frame: randomization day and 12 months post randomization.

Change in MLwHF form

Minnesota Living with Heart Failure - Quality of life self-administered survey focusing on heart failure symptoms (21 items with 1 : slightly to 5 : al lot) Safety issue? 0 Yes 1 No

Time frame: randomization day and 12 months post randomization.

Change in SF36 form

Short Form 36 : Quality of life self-administered survey with 36 items about 8 dimensions including a physical and mental score.

Time frame: randomization day and 12 months post randomization.

Death occurrence attributable to ultrafiltration technique

Safety: Death occurrence attributable to ultrafiltration technique, validated by an independent supervisory board, and any adverse event.

Time frame: up to 12 months post- randomization

Change in Brain Natriuretic Peptide and/or NT-Probating Natriuretic Peptide rate

Following biological features variation : Brain Natriuretic Peptide (BNP) and/or NT-ProBNP